Novo Nordisk (NOV) Price & Analysis

Compare

508 Followers

NOV Stock Chart & Stats

Day’s Range― - ―

52-Week Range€38.54 - €111.36

Previous CloseN/A

Volume21.06K

Average Volume (3M)355.62K

Market Cap

kr225.20B

Enterprise Value€2.04T

Total Cash (Recent Filing)kr41.55B

Total Debt (Recent Filing)kr118.72B

Price to Earnings (P/E)15.1

Beta0.73

Next Earnings

Nov 05, 2025

EPS Estimate

0.67

Last Dividend Ex-Date

Aug 15, 2025

Dividend Yield3.04%

Share Statistics

EPS (TTM)0.80

Shares Outstanding3,390,128,000

10 Day Avg. Volume376,866

30 Day Avg. Volume355,620

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

kr58.90

Price Target Upside16.31% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering13

Bulls Say, Bears Say

Bulls Say

Market StrategyNovo Nordisk is proactively engaging with physicians to optimize dosing strategies, which could enhance the safety and tolerability profile of its products.

Product DevelopmentNovo Nordisk's trial for Rybelsus in Alzheimer's could be clinically meaningful even with modest benefits, thanks to its broad safety profile.

Regulatory ProgressNovo Nordisk confirmed the filing of the Semaglutide 7.2mg dose in the US, indicating regulatory progress.

Bears Say

Earnings GuidanceNovo announced an EBIT guide cut on restructuring costs, with the guide range lowered significantly, making the net benefit unclear.

Prescription TrendsThe TRx trajectory for Wegovy/Ozempic trends is still lacklustre, with Wegovy TRx now flat for 6 weeks and Ozempic still flat.

Sales PerformanceThere is a risk of a top-end sales guide cut for FY25, with implications continuing into FY26, due to disappointing sales trajectories.

Novo Nordisk News

Moderately bullish activity in Novo Nordisk with shares down 0.92%

Moderately bullish activity in Novo Nordisk (NVO), with shares down 55c near $58.62. Options volume roughly in line...

4d ago

NVO

Novo Nordisk upgraded to Buy from Hold at HSBC (yesterday)

HSBC analyst Rajesh Kumar upgraded Novo Nordisk (NVO) to Buy from Hold with a $70 price target The...

5d ago

NVO

Novo Nordisk upgraded to Buy from Hold at HSBC

HSBC upgraded Novo Nordisk (NVO) to Buy from Hold with a $70 price target Published first on TheFly...

5d ago

NVO

Moderately bullish activity in Novo Nordisk with shares down 1.23%

Moderately bullish activity in Novo Nordisk (NVO), with shares down 68c near $54.81. Options volume running well above...

6d ago

NVO

LifeMD offers Ozempic at $499 per month via Novo Nordisk collaboration

LifeMD (LFMD) announced an additional offering through its collaboration with Novo Nordisk (NVO) that provides access to Ozempic,...

6d ago

NVO

LFMD

EA acquired in go-private deal for $55B, Carnival reports Q3 beat: Morning Buzz

The major averages were mixed near noon as the Street attempts to regain its footing after stocks ended...

7d ago

Morning Movers: Tilray rises as Trump touts CBD benefits for seniors

Stock futures rose on Monday as investors weighed the potential impact of a possible U.S. government shutdown, which...

7d ago

NVO

Novo Nordisk downgraded to Underweight from Equal Weight at Morgan Stanley

Morgan Stanley downgraded Novo Nordisk (NVO) to Underweight from Equal Weight with a price target of $47, down...

8d ago

NVO

Pfizer gains ‘impressive obesity portfolio’ with Metsera deal, says BofA

After Pfizer (PFE) announced an agreement to acquire Metsera (MTSR) for $4.9B upfront and total potential deal value...

12d ago

LLY

NVO

Scholar Rock price target lowered to $44 from $50 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Scholar Rock (SRRK) to $44 from $50 and keeps a...

13d ago

NVO

SRRK

Cautious Outlook for Novo Nordisk Amid Uncertain Pipeline Outcomes and Growth Challenges

Analyst Sachin Jain of Bank of America Securities maintained a Hold rating on Novo Nordisk, with a price...

18d ago

NVO

Hold Rating for Novo Nordisk Amid Restructuring and Market Challenges

Analyst Sachin Jain of Bank of America Securities maintained a Hold rating on Novo Nordisk, with a price...

26d ago

NVO

Novo Nordisk’s Strategic Restructuring Faces Uncertainty Amid Competitive Pressures

In a report released today, Evan Seigerman from BMO Capital maintained a Hold rating on Novo Nordisk, with...

26d ago

NVO

Novo Nordisk’s Strategic Focus on Obesity Market and Oral Semaglutide Drives Buy Rating

In a report released today, Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk, with...

2M ago

NVO

NOV FAQ

What was Novo Nordisk’s price range in the past 12 months?

Novo Nordisk lowest stock price was €38.54 and its highest was €111.36 in the past 12 months.

What is Novo Nordisk’s market cap?

Novo Nordisk’s market cap is kr225.20B.

When is Novo Nordisk’s upcoming earnings report date?

Novo Nordisk’s upcoming earnings report date is Nov 05, 2025 which is in 30 days.

How were Novo Nordisk’s earnings last quarter?

Novo Nordisk released its earnings results on Aug 06, 2025. The company reported €0.798 earnings per share for the quarter, beating the consensus estimate of €0.795 by €0.004.

Is Novo Nordisk overvalued?

According to Wall Street analysts Novo Nordisk’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Novo Nordisk pay dividends?

Novo Nordisk pays a Semiannually dividend of €0.502 which represents an annual dividend yield of 3.04%. See more information on Novo Nordisk dividends here

What is Novo Nordisk’s EPS estimate?

Novo Nordisk’s EPS estimate is 0.67.

How many shares outstanding does Novo Nordisk have?

Novo Nordisk has 3,390,128,000 shares outstanding.

What happened to Novo Nordisk’s price movement after its last earnings report?

Novo Nordisk reported an EPS of €0.798 in its last earnings report, beating expectations of €0.795. Following the earnings report the stock price went down -4.577%.

Which hedge fund is a major shareholder of Novo Nordisk?

Currently, no hedge funds are holding shares in DE:NOV

Company Description

Novo Nordisk

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novo Nordisk (NOV) Earnings & Revenues

Historic Earnings Reports

NOV Stock 12 Month Forecast

Average Price Target

€58.90

▲(16.31% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"40":"€40","56":"€56","72":"€72","88":"€88","104":"€104"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":80.3598,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€80.36</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":58.89703675,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€58.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45.53722,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€45.54</span>\n  </div></div>","useHTML":true}}],"tickPositions":[40,56,72,88,104],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50.07,52.39998461538462,54.72996923076923,57.059953846153846,59.38993846153846,61.71992307692308,64.0499076923077,66.3798923076923,68.70987692307693,71.03986153846154,73.36984615384615,75.69983076923077,78.02981538461539,{"y":80.3598,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50.07,50.749002826923075,51.42800565384616,52.10700848076923,52.786011307692306,53.46501413461539,54.14401696153846,54.82301978846154,55.50202261538462,56.18102544230769,56.86002826923077,57.53903109615385,58.21803392307692,{"y":58.89703675,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50.07,49.72132461538462,49.372649230769234,49.023973846153844,48.67529846153846,48.32662307692308,47.977947692307694,47.629272307692304,47.28059692307692,46.93192153846154,46.583246153846154,46.234570769230764,45.88589538461538,{"y":45.53722,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":103.754,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.351,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.837,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.418,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.367,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.034,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.389,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.666,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.667,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.842,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.168,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.92,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.07,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >